Tumor Infiltrating Lymphocytes (TIL) in Solid Tumors: Emerging Insights
This special issue belongs to the section "Molecular Cancer Biology".
Special Issue Information
Dear Colleagues,
The introduction of immune checkpoint inhibitors (ICI) in the management of a multitude of malignancies has improved survival outcomes. A subset of breast cancer (BC) patients has immunogenic tumors with notable lymphocytic infiltration and marked programmed death ligand 1 (PD-L1) expression which may indicate benefit from programmed death 1 (PD-1)/PD-L1 blockade. Emerging data suggest TILs (tumor-infiltrating lymphocytes) predict response to both cytotoxic treatments and immunotherapy. TILs can be assessed using manual methods or with machine learning methods. Integrating machine learning tools necessitates quality standards, performance metrics, and a regulatory framework before introduction in a clinical trial setting and/or daily practice setting can be considered.
The current Special Issue aims to provide a forum for discussing pathologist and algorithm performance assessment studies and methods, inform the scientific community on the potential use of TILs in daily practice, and explore the use of computer aids and automation for TIL evaluation in cancer care, including the appropriate regulatory framework.
Dr. Roberto Salgado
Dr. Brandon D. Gallas
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumor-infiltrating lymphocytes
- machine learning
- clinical validity and utility
- pathologist agreement
- algorithm assessment
- daily practice
- regulatory issues
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Published Papers
Cancers - ISSN 2072-6694